معرفی
Dr. Michael Thomas is a Medicinal Chemist affiliated with the Drug Discovery Unit in the United Kingdom. His research focuses on drug discovery for parasitic diseases such as Chagas disease and visceral leishmaniasis, with a particular emphasis on developing novel inhibitors targeting Trypanosoma cruzi and Leishmania species. He has contributed to over 20 peer-reviewed articles and co-authored key studies on proteasome inhibitors, structure-activity relationships, and drug design strategies for neglected tropical diseases.
His work aligns with UN Sustainable Development Goals addressing global health challenges. Recent publications highlight advancements in proteasome inhibition mechanisms, pyridazinone series development, and structural insights for site-specific drug candidates. He was part of a team honored with the 2023 Industry and Academic Collaboration Award for contributions to drug discovery in kinetoplastid diseases.
Thomas collaborates extensively with international teams on projects targeting parasitic pathogens, demonstrating expertise in both chemical synthesis and biological validation of drug candidates.
